DLA Piper has advised Alimera Sciences, Inc., a global pharmaceutical company focused on ophthalmic solutions, in its acquisition by ANI Pharmaceuticals. The transaction, valued at approximately US$381 million in upfront consideration plus contingent value rights based on achieving revenue milestones, remains subject to customary closing conditions, including regulatory approvals and shareholder agreement. Alimera is known for its products ILUVIEN and YUTIQ, addressing diabetic macular edema and chronic non-infectious uveitis. ANI Pharmaceuticals, a diversified biopharmaceutical company, continues to expand its portfolio through this strategic move. DLA Piper’s Andrew Gilbert led the legal advisory team. The firm’s extensive experience in handling intricate transactions and deep insights within the life sciences sector played a pivotal role in this deal.

Pharmaceuticals, Biotechnology, Legal Advisory,United States, Global